Heron Therapeutics, Inc. (HRTX) is a publicly traded Healthcare sector company. As of May 21, 2026, HRTX trades at $0.89 with a market cap of $162.67M and a P/E ratio of -5.01. HRTX moved +0.18% today. Year to date, HRTX is -31.85%; over the trailing twelve months it is -55.98%. Its 52-week range spans $0.74 to $2.68. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces HRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Heron Therapeutics Sustains Q1 Growth, Advances Late-Stage Pain Pipeline: Heron Therapeutics sustained year-over-year revenue gains in Q1 2026 despite increased R&D spending tied to its analgesic portfolio expansion. Management confirmed full-year guidance and highlighted initiation of pivotal trials for its late-stage pain management candidates.
| Metric | Value |
|---|---|
| Price | $0.89 |
| Market Cap | $162.67M |
| P/E Ratio | -5.01 |
| EPS | $-0.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.68 |
| 52-Week Low | $0.74 |
| Volume | 28 |
| Avg Volume | 0 |
| Revenue (TTM) | $150.71M |
| Net Income | $-30.94M |
| Gross Margin | 71.12% |
2 analysts cover HRTX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.50.